Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world adjuvant atezolizumab study in resected stage II-IIIB NSCLC
ChiCTR2500103083Phase 4Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: 2-year disease-free survival rate and 2-year overall survival rate. Started May 2025; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500103083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103083.